Sarepta Therapeutics Inc (SRPT) 12.76 $SRPT
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
Business Wire - Wed Feb 04, 7:30AM CST
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that management is scheduled to participate in fireside chats at the following investor conferences in February. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
SRPT: 12.76 (+0.11)
Why Sarepta Therapeutics Inc. Shares Crashed 17% in January
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 03, 7:15AM CST
SRPT data by YCharts What: Shares of Sarepta Therapeutics , a clinical-stage biopharmaceutical company primarily focused on developing therapies to treat Duchenne muscular dystrophy, crashed 17% in January per data from S&P Capital IQ ...
SRPT: 12.76 (+0.11)
INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Fri Jan 30, 9:32AM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of purchasers of the securities of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
(NASDAQ:SRPT) between April 21, 2014 and October 27, 2014, inclusive (the "Class Period" .
SRPT: 12.76 (+0.11)
UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT
GlobeNewswire - Thu Jan 29, 9:03AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company" (Nasdaq:SRPT) securities between April 21, 2014 and October 27, 2014.
SRPT: 12.76 (+0.11)
ALERT: Rosen Law Firm Reminds Sarepta Therapeutics Investors of Important February 9, 2015 Deadline in Class Action Seeking to Recover Investor Losses -- SRPT
GlobeNewswire - Mon Jan 26, 5:40PM CST
Rosen Law Firm reminds purchasers of Sarepta Therapeutics, Inc. securities (Nasdaq:SRPT) during the period from April 21, 2014 through October 27, 2014 of the important February 9, 2015 lead plaintiff deadline in the class action lawsuit.
SRPT: 12.76 (+0.11)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
State of the Union Address Investing Idea: Precision Medicine
Brian Orelli, The Motley Fool - Motley Fool - Wed Jan 21, 1:43PM CST
From education to foreign policy to immigration, President Barack Obama covered a lot in his State of the Union speech on Tuesday evening. While healthcare was a minor part of the address, it stood out as one of the most investible topics mentioned...
BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), BMRN: 100.76 (+1.98), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), ALXN: 182.29 (+6.02), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sarepta Therapeutics, Inc.
Business Wire - Tue Jan 20, 11:32AM CST
Glancy Binkow & Goldberg LLP reminds investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company" (NASDAQ:SRPT) that purchasers of Sarepta securities between April 21, 2014 and October 27, 2014, inclusive (the "Class Period" , have until February 6, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of Massachusetts.
SRPT: 12.76 (+0.11)
8 Biotech Stock Controversies Emerging From 'JPM15' Conference
at The Street - Tue Jan 20, 9:18AM CST
The J.P. Morgan Healthcare Conference is in the rear-view mirror, but issues, controversies and questions raised during the annual gathering of the biotech sector tribe will linger through the year.
BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), SRPT: 12.76 (+0.11), AGIO: 118.55 (+0.11)
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), PFE: 34.64 (-0.23), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 5.00 (-0.07), ISIS: 63.86 (-0.43), SRPT: 12.76 (+0.11)
Seeking Alpha's Biotech Weekly: Roche Takes Control, Shire's A Buyer, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 16, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ZIOP: 9.64 (-0.35), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNKD: 7.00 (+0.02), RGDO: 1.17 (+0.02), HUM: 152.67 (-1.06), ETRM: 1.21 (+0.06), FMI: 48.88 (+0.17), GILD: 101.90 (+1.10), GERN: 3.03 (unch), SHPG: 239.82 (+6.11), SRPT: 12.76 (+0.11)
Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 3:30PM CST
Sarepta Therapeutics Inc. (SRPT) announced that it has initiated dosing its first patient in a phase I/II study on SRP-4053.
SRPT: 12.76 (+0.11), ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), BIOD: 1.38 (-0.14)
Sarepta Is Suffering From Overreaction
Value Insight - at Seeking Alpha - Thu Jan 15, 8:00AM CST
SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT
PR Newswire - Wed Jan 14, 11:43AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company" (NASDAQ: SRPT) securities between April 21, 2014 and October 27, 2014.
SRPT: 12.76 (+0.11)
Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients
Business Wire - Wed Jan 14, 7:30AM CST
Sarepta Therapeutics Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing of SRP-4053 in its first human trial, a Phase I/II study in Duchenne muscular dystrophy (DMD). This multiple-dose study will assess the safety, tolerability, efficacy, and pharmacokinetics of SRP-4053 in DMD patients with genotypes amenable to exon-53 skipping.
SRPT: 12.76 (+0.11)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 13, 5:15PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
DISCK: 30.32 (+0.80), ARWR: 6.77 (+0.21), AFMD: 5.70 (-0.25), TFM: 37.14 (+0.07), SRPT: 12.76 (+0.11), DISCB: 31.64 (+0.64), DISCA: 31.45 (+1.11), POZN: 6.95 (+0.15), PEIX: 9.82 (+0.15), GFN: 9.20 (+0.25), HLSS: 16.15 (-0.14), DXPE: 46.57 (+1.42), OBAS: 6.25 (-0.05)
Today's Dead Cat Bounce Stock: Sarepta Therapeutics (SRPT)
at The Street - Tue Jan 13, 8:49AM CST
Trade-Ideas LLC identified Sarepta Therapeutics (SRPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
SRPT: 12.76 (+0.11)
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
Business Wire - Wed Feb 04, 7:30AM CST
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that management is scheduled to participate in fireside chats at the following investor conferences in February. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
SRPT: 12.76 (+0.11)
Why Sarepta Therapeutics Inc. Shares Crashed 17% in January
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 03, 7:15AM CST
SRPT data by YCharts What: Shares of Sarepta Therapeutics , a clinical-stage biopharmaceutical company primarily focused on developing therapies to treat Duchenne muscular dystrophy, crashed 17% in January per data from S&P Capital IQ ...
SRPT: 12.76 (+0.11)
INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Fri Jan 30, 9:32AM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of purchasers of the securities of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
(NASDAQ:SRPT) between April 21, 2014 and October 27, 2014, inclusive (the "Class Period" . SRPT: 12.76 (+0.11)
UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT
GlobeNewswire - Thu Jan 29, 9:03AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
(Nasdaq:SRPT) securities between April 21, 2014 and October 27, 2014. SRPT: 12.76 (+0.11)
ALERT: Rosen Law Firm Reminds Sarepta Therapeutics Investors of Important February 9, 2015 Deadline in Class Action Seeking to Recover Investor Losses -- SRPT
GlobeNewswire - Mon Jan 26, 5:40PM CST
Rosen Law Firm reminds purchasers of Sarepta Therapeutics, Inc. securities (Nasdaq:SRPT) during the period from April 21, 2014 through October 27, 2014 of the important February 9, 2015 lead plaintiff deadline in the class action lawsuit.
SRPT: 12.76 (+0.11)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
State of the Union Address Investing Idea: Precision Medicine
Brian Orelli, The Motley Fool - Motley Fool - Wed Jan 21, 1:43PM CST
From education to foreign policy to immigration, President Barack Obama covered a lot in his State of the Union speech on Tuesday evening. While healthcare was a minor part of the address, it stood out as one of the most investible topics mentioned...
BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), BMRN: 100.76 (+1.98), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), ALXN: 182.29 (+6.02), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sarepta Therapeutics, Inc.
Business Wire - Tue Jan 20, 11:32AM CST
Glancy Binkow & Goldberg LLP reminds investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
(NASDAQ:SRPT) that purchasers of Sarepta securities between April 21, 2014 and October 27, 2014, inclusive (the "Class Period" , have until February 6, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of Massachusetts. SRPT: 12.76 (+0.11)
8 Biotech Stock Controversies Emerging From 'JPM15' Conference
at The Street - Tue Jan 20, 9:18AM CST
The J.P. Morgan Healthcare Conference is in the rear-view mirror, but issues, controversies and questions raised during the annual gathering of the biotech sector tribe will linger through the year.
BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), SRPT: 12.76 (+0.11), AGIO: 118.55 (+0.11)
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), PFE: 34.64 (-0.23), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 5.00 (-0.07), ISIS: 63.86 (-0.43), SRPT: 12.76 (+0.11)
Seeking Alpha's Biotech Weekly: Roche Takes Control, Shire's A Buyer, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 16, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ZIOP: 9.64 (-0.35), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNKD: 7.00 (+0.02), RGDO: 1.17 (+0.02), HUM: 152.67 (-1.06), ETRM: 1.21 (+0.06), FMI: 48.88 (+0.17), GILD: 101.90 (+1.10), GERN: 3.03 (unch), SHPG: 239.82 (+6.11), SRPT: 12.76 (+0.11)
Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 3:30PM CST
Sarepta Therapeutics Inc. (SRPT) announced that it has initiated dosing its first patient in a phase I/II study on SRP-4053.
SRPT: 12.76 (+0.11), ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), BIOD: 1.38 (-0.14)
Sarepta Is Suffering From Overreaction
Value Insight - at Seeking Alpha - Thu Jan 15, 8:00AM CST
SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT
PR Newswire - Wed Jan 14, 11:43AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
(NASDAQ: SRPT) securities between April 21, 2014 and October 27, 2014. SRPT: 12.76 (+0.11)
Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients
Business Wire - Wed Jan 14, 7:30AM CST
Sarepta Therapeutics Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing of SRP-4053 in its first human trial, a Phase I/II study in Duchenne muscular dystrophy (DMD). This multiple-dose study will assess the safety, tolerability, efficacy, and pharmacokinetics of SRP-4053 in DMD patients with genotypes amenable to exon-53 skipping.
SRPT: 12.76 (+0.11)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jan 13, 5:15PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
DISCK: 30.32 (+0.80), ARWR: 6.77 (+0.21), AFMD: 5.70 (-0.25), TFM: 37.14 (+0.07), SRPT: 12.76 (+0.11), DISCB: 31.64 (+0.64), DISCA: 31.45 (+1.11), POZN: 6.95 (+0.15), PEIX: 9.82 (+0.15), GFN: 9.20 (+0.25), HLSS: 16.15 (-0.14), DXPE: 46.57 (+1.42), OBAS: 6.25 (-0.05)
Today's Dead Cat Bounce Stock: Sarepta Therapeutics (SRPT)
at The Street - Tue Jan 13, 8:49AM CST
Trade-Ideas LLC identified Sarepta Therapeutics (SRPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
SRPT: 12.76 (+0.11)
